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ABSTRACT: Introduction: Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are considered part of the same pathological spectrum. There is an increased risk of ALS in patients who have had melanoma. The risk of FTLD in melanoma (or cancer) patients is unknown. We aimed to study if C9ORF72 expansion is linked to a higher prevalence of melanoma. Methods: We selected patients with a diagnosis in the ALS-FTLD spectrum who were tested for pathogenic mutations. Medical history was reviewed, to identify those with pathologically documented melanomas. Results: We included 189 patients. Sixty-two had identified pathogenic mutations (39 C9ORF72). C9ORF72 carriers had a significantly higher risk of melanoma (odds ratio = 24.709; P < 0.007). There was no association with phenotype. Conclusions: These findings suggest that patients with a history of melanoma may have an increased probability of carrying a C9ORF72 repeat expansion. ALS or FTLD carriers of C9ORF72 should undergo surveillance for skin changes.
Muscle Nerve 59: [362] [363] [364] 2019 Several studies have examined the risk of cancer in neurodegenerative diseases, including Parkinson and Alzheimer diseases, which have been reported to have a protective effect against the overall development of cancer. [1] [2] [3] [4] [5] The same overall protective effect has been reported recently in amyotrophic lateral sclerosis (ALS), 6 but some types of cancer seem to have increased prevalence in this population. There is mounting evidence of an increased risk of ALS in patients who have had melanoma. 7, 8 ALS and frontotemporal lobar degeneration (FTLD) are considered part of the same pathological spectrum and share common pathogenic genetic mutations, with the chromosome 9 open reading frame 72 (C9ORF72) expansion being the most common in both. 9 A small study in FTLD reports overall lower risk of cancer. 10 Several genes have been implicated in the association between cancer and neurodegenerative diseases, including progranulin (GRN), 11 fused-in-sarcoma (FUS), 12 and SQSTM1. 13 However, we still lack the understanding of the underlying mechanism that would explain such association. 14 Exploring the relationship between cancer and neurodegenerative diseases could provide new clues relevant to the etiologies and potential therapies for both sets of conditions.
Of interest, analysis of skin biopsies of C9ORF72 repeat expansion ALS patients revealed early TDP-43 deposition and abnormal extracellular matrix findings, 15 suggesting a possible link between this expansion and skin disease.
We aimed to study the hypothesis that C9ORF72 expansion is linked to a higher prevalence of melanoma. department with the most recent appointment between 2010 and 2017, who were tested for pathogenic mutations in superoxide dismutase (SOD), TANK-binding kinase 1 (TBK1), GRN, microtubule-associated protein tau (MAPT), valosincontaining protein (VCP), FUS, charged multivesicular body protein 2B (CHMP2B), or C9ORF72 repeat expansions.
This study was approved by our hospital ethical committee, and all patients or their close relatives gave consent for data collection.
Methods. We reviewed all subjects' medical history to identify those with histopathologically documented melanoma during their lifetime. This was done with the families (and the patients whenever they could give reliable information) and by reviewing all the patients' medical records.
To investigate a possible link between c90rf72 repeat expansion and melanoma, we compared the risk of melanoma between C9ORF72 repeat expansion carriers and all patients who tested negative for C9ORF72 expansion. We further compared the risk of melanoma between C9ORF72 carriers and patients with other identified pathogenic mutations.
We also compared melanoma prevalence across different phenotypes and basal cell carcinoma prevalence between C9ORF72 carriers and noncarriers.
Statistical Analysis. Statistical analysis was performed using SPSS statistical software (version 20.0; SPSS Inc., Chicago, IL). Categorical data are presented as frequency (percentage) and were compared using χ 2 -test. Continuous variables were compared using Student's t-test. To estimate the association between carrying a C9ORF72 expansion and developing melanoma, a logistic regression was performed to calculate the odds ratio, adjusted for age. A Bejamini-Hochberg post hoc correction for multiple comparisons was performed, giving a α = 0.0083).
RESULTS
We included 189 patients. Of those, 157 patients had a primary FTLD diagnosis and 32 an ALS diagnosis. Of the total, 62 had identified pathogenic mutations: 39 subjects had C9ORF72 repeat expansions, 3 had MAPT mutations, and 20 had GRN mutations. Patient diagnosis and mutation status are provided in Table 1 .
The mean age of all subjects was of 63.8 (AE10.5) years. Mutation carriers were significantly younger (59.3 AE 10.4 years; P < 0.001), as were the C9ORF72 expansion carriers (60.6 AE 10.7 years old; P = 0.031). 54.5% of the population was male, and there were no gender differences between groups.
Seven patients had a diagnosis of melanoma; 6 of them were carriers of a C9ORF72 repeat expansion, and the other had no identified mutation. Three additional patients had basal cell carcinoma: 2 of them were C9ORF72 expansion carriers and 1 had no identified pathogenic mutation. All the 6 patients with a C9ORF72 expansion and melanoma (15.4% of the C9ORF72 carriers) belonged to 4 unrelated families. Five of them had ALS and one had FTLD. Three of them were from the same family (7 members carrying the mutation and manifesting disease, 3 of whom had melanoma). The patient with melanoma without a pathogenic mutation was unrelated to any of the patients with melanoma.
As depicted in FIGURE 1, C9ORF72 carriers had a significantly higher prevalence of melanoma (P < 0.001), comparing with all the other patients with a negative test for this expansion (odds ratio = 24.709; 95% confidence interval, 2.440-249.804; P < 0.007; Nagelkerke R square of 0.259; χ 2 = 10.637). Compared only with other mutation carriers, melanoma prevalence was still significantly higher (P = 0.048). There was association with neither FTLD nor ALS (P = 0.216) in C9ORF72 carriers.
Other melanoma-causing mutations were excluded in the two living C9ORF72 carriers with history of melanoma. CDKN2A was tested in the 2 patients with melanoma and C9ORF72 repeat expansions and were negative. One of the patients was further studied for CDK4, MC1R, CDKN2B, and GNAQ and was negative for pathogenic mutations in those genes.
DISCUSSION
Our study suggests a link between C9ORF72 repeat expansions and increased risk of melanoma. Additionally, melanoma's prevalence in C9ORF72 carriers is higher than that of basal cell carcinoma, which is the inverse of the general population. 16 Several previous studies analyzing the risk of ALS in cancer patients revealed a link between both conditions. None of these studies analyzed the role of specific mutations in this association. We speculate that the increased risk of melanoma found in those studies can be (at least partially) due to the existence of occult C9ORF72 repeat expansion carriers on those samples. It could also be that a common pathway is involved in the ALS/FTLD spectrum and melanoma development, in which C9ORF72 repeat expansions may play a role.
It has been shown that TDP-43 nuclear overexpression with no cytoplasmic inclusions can be detected in skin biopsies from ALS patients. 15 In addition, analysis of cultured fibroblasts and keratinocytes from skin biopsies of C9ORF72 repeat expansion ALS patients reveals abnormal extracellular matrix findings, such as epidermal undifferentiation, abnormal dermoepidermal junction, delamination keratinocyte infiltration, and collagen disorganization. 17 Consistently, an in silico bioinformatics data mining analysis of the molecular network of C9ORF72 showed a down-regulation of collagen-related genes as well as genes implicated in the assembly, synthesis, and cross-linking of collagen fibrils. 18 These findings suggest that cytoskeletal dynamics and/or remodeling of extracellular matrix disturbances might be key factors of the disease and associate C9ORF72 repeat expansions with those changes, possibly increasing the risk for melanoma.
One possible bias would be genetic linkage of the C9ORF72 repeat expansion to a mutation in a nearby gene involved in melanoma development. Several gene mutations have been associated with melanoma, namely CDK4, CDKN2A, GNAQ, RB1, PPP6C, RAC1, SNX31, TACC1, STK19, ARID2, BRAF, NRAS, HRAS, TERT, KIT, TP53, EGFR, ERBB4, PIK3CA, PDGFRA.
19 Some of these (CDKN2A and GNAQ) localize in the short arm of the chromosome 9. CDKN2A was tested in the 2 patients with melanoma and C9ORF72 repeat expansions and was negative. One of the patients was further studied for CDK4, MC1R, CDKN2B, and GNAQ somatic mutations and was negative for pathogenic mutations in those genes. A phenomenon of epistasis between C9ORF72 and CDKN2A or GNAQ is also possible, given their relative proximity, and should be further addressed.
The major limitation of this work is the low number of melanomas, with half of them coming from the same family. There may be an underlying mutation or environmental risk factor that we did not identify. However, even if we exclude those patients, the difference would still be significantly higher (P = 0.002). Also, there was a statistically significant difference in the ages of the groups. This was expected given the lower age of onset of patients with pathogenic mutations. However, this difference is only 3 years, and if affecting the prevalence of melanoma, would only potentially increase the difference, as they had less time to develop melanoma.
These findings suggest that ALS or FTLD patients with a personal history of melanoma may be at increased risk of carrying a C9ORF72 repeat expansion, and that genetic testing for C9ORF72 might be considered in those patients. Carriers of C9ORF72 should undergo surveillance for skin changes.
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